Loading
Exercise is the best-evidenced thing a person can do for their own recovery, and the guidelines put a number on it: moderate aerobic exercise at least three times a week for at least thirty minutes, for eight to twelve weeks, plus resistance training twice a week, two sets of eight to fifteen repetitions at sixty per cent or more of the heaviest weight you can lift once.
The 2018 international roundtable convened by the American College of Sports Medicine reviewed the randomised evidence outcome by outcome and wrote the prescription down. Its summary sentence is that an effective prescription "includes moderate intensity aerobic training at least 3 times per week, for at least 30 minutes, for at least 8-12 weeks", and that adding resistance training "at least 2 times per week, using at least 2 sets of 8-15 repetitions at least 60% of one repetition maximum, appears to results in similar benefits". Doses differ a little by outcome: for cancer-related fatigue the roundtable's table gives aerobic training at about 65 per cent of maximum heart rate, 30 minutes, three times a week for 12 weeks, or resistance training at 60 per cent of one-repetition maximum, two sets of 12 to 15 repetitions, twice a week for 12 weeks. For anxiety and depressive symptoms, supervised programmes worked better than unsupervised ones; for fatigue, supervised and unsupervised were similarly effective. For lymphoedema the table prescribes resistance training at 60 to 70 per cent of one-repetition maximum, one to three sets of 8 to 15 repetitions, two to three times a week for a year, started under supervision.
The roundtable concluded that "exercise training and testing were generally safe for cancer survivors and that every survivor should 'avoid inactivity'", and that there was enough evidence for benefit on "anxiety, depressive symptoms, fatigue, physical functioning, and health-related quality of life". It was equally plain about the limits: "Implications for other outcomes, such as peripheral neuropathy and cognitive functioning, remain uncertain."
ASCO's 2022 guideline covers the treatment period rather than after it, and recommends that clinicians "recommend regular aerobic and resistance exercise during active treatment with curative intent". The CHALLENGE trial (NEJM 2025) took the next step and showed a survival benefit in colon cancer, which no supplement, infusion or clinic programme sold as rejuvenation has shown in any cancer.
What comes back, and when: fitness is the most recoverable thing on this page. Aerobic capacity and strength fall during treatment and rise again with training, in trials lasting eight to twelve weeks rather than years. The honest limit is that the roundtable found no reliable effect of exercise on nerve damage or on measured cognition, so it should not be sold as a fix for those.
Aerobic and resistance training raise cardiorespiratory capacity and muscle cross-sectional area, lower circulating insulin, IGF-1 and inflammatory signalling, and improve the physical reserve that treatment depletes. The dose matters: the trials that worked prescribed frequency, intensity, time and type, not a recommendation to be active.
Query for this technology: (TITLE:"The exercise prescription after cancer: the dose the guidelines state" OR ABSTRACT:"The exercise prescription after cancer: the dose the guidelines state") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about The exercise prescription after cancer: the dose the guidelines state, not a curated reading list.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Bone loss caused by cancer treatment, and what rebuilds it, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Bone loss caused by cancer treatment, and what rebuilds it, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected, Toxicity and quality of life are undervalued and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Toxicity and quality of life are undervalued, HR-positive / HER2-negative breast cancer and the tags rejuvenation, survivorship.